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Abstract
           
Background:  Cardiac Resynchronization Therapy (CRT) is indicated for the treatment of 
advanced heart failure with severe systolic dysfunction and intraventricular conduction delay. 
Patient selection for this technology is vital, though it remains unclear which patients benefit 
most from CRT. We tested the hypothesis that patients with non-ischemic cardiomyopathy have 
a superior mortality benefit from CRT than ischemic cardiomyopathy patients.                
Methods:  We  evaluated  95  CRT  patients   to  determine  which  factors   predict  mortality.
Results: Patients with non-ischemic cardiomyopathy had a significantly better prognosis than 
patients   with   ischemic   cardiomyopathy.                                                                  
Conclusion: Larger prospective studies can substantiate this finding and better delineate which 
patients   benefit   most   from   CRT.                                                        
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Introduction
            Patients with heart failure may remain symptomatic despite the use of pharmacological 
treatment. Many of these patients have wide QRS intervals leading to asynchronous contraction 
of the ventricles. Cardiac resynchronization therapy (CRT) improves cardiac hemodynamics, 
reduces   clinical   symptoms   and   decreases   morbidity   and   mortality   in   these   patients.1-6 
               The criteria for CRT placement have changed since the advent of biventricular 
pacemakers. While many patients with heart failure benefit from CRT, it is still unclear which 
patients are ideal candidates for biventricular pacing. We sought to identify which patients 
benefit   most   from   CRT.                                                                          
Methods
            Ninety five consecutive patients who had a bi-ventricular pacemaker inserted at Beth 
Israel Medical Center between 7/02 and 11/05 were evaluated. All patient characteristics and 
clinical measures assessed prior to pacemaker implantation were analyzed to determine their 
impact on patient survival: age, gender, etiology of cardiomyopathy, bundle type, ejection 
fraction, left ventricular end diastolic dimension (LVEDD), and QRS complex duration. Patients 
whose EKG was paced prior to biventricular pacemaker insertion were not included in analysis 
for   bundle   type   and   QRS   duration.                                                          
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             Univariate log-rank tests were initially used to investigate possible relationships (at p ≤ .
10) between survival and each patient characteristic.   Subsequent multivariate analysis of 
potential risk factors for survival controlling for age was performed using Cox proportional 
hazards analyses. The partial likelihood ratio test was used to assess parameter significance at p 
≤ .05. The study was approved by the Beth Israel Medical Center Institutional Review Board.
Results
            Baseline characteristics are shown in Table 1. 
Table 1
LVEDD= left ventricular end diastolic diameter; ARB= angiotensin II receptor blockers
            Age at time of pacemaker implantation varied from 33 to 89 years, with a median of 70 
years.  Mean duration of follow-up was 1.6 years.   Twenty one patients (22% of males and 23% 
of females) died prior to study end-date, with death occurring 0.1 to 2 years (median 0.5 years) 
after pacemaker implantation.  To date, the duration of survival for the other 74 patients ranges 
from   0.7   to   3.9   years   (median   1.7   years).
            Initial log-rank tests revealed that age and etiology of heart disease were strongly related 
to survival (Table 2).  
Table 2
LVEDD= left ventricular end diastolic diameter; IVCD= intraventricular conduction defect; 
BBB= bundle branch block
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             31% of patients with ischemic cardiomyopathy reached the endpoint of death versus 
13% of patient with non-ischemic cardiomyopathy (p<.05; hazard ratio 3.29). Survival was not 
associated with gender, ejection fraction, QRS length, bundle type, or LVEDD. In addition, there 
was   no   medication   associated   with   decreased   mortality.                                        
Discussion
               The present study investigated whether any pre-CRT baseline characteristics were 
associated with a better prognosis than other baseline characteristics. Our data demonstrated that 
patients with non-ischemic cardiomyopathy had decreased mortality with CRT compared to 
patients with ischemic cardiomyopathy. Our finding are consistent with prior studies.1 In CARE-
HF study 54% of patients with ischemic cardiomyopathy reached the primary endpoint of death 
or major cardiac event versus 39% of patients with non-ischemic cardiomyopathy (p<.0001).  
            There are two main limitations of our study. Our data is retrospective and we don't have 
all baseline characteristics on all 95 patients. In addition, we were unable to evaluate for any 
subjective  functional   improvements  with   CRT  in  the  different  groups.                       
            The present study suggested that non-ischemic cardiomyopathy patients with CRT have a 
better prognosis than ischemic cardiomyopathy patients with CRT. Prospective studies, with 
larger samples specifically evaluating etiology of cardiomyopathy in CRT patients are needed to 
substantiate   this   finding.                                                              
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